A cluster of blood cells

NEW to decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

DECREASED RATE OF DOSE REDUCTIONS

PIVOTAL STUDY SECONDARY ENDPOINTS: The number of all-cause dose reductions, events per 100 cycles, was significantly lower with COSELA™ (trilaciclib), 2.1 vs 8.5 without COSELA (ARR: 0.242 [95% CI, 0.079, 0.742], P=0.0195). Dose reductions of Carboplatin and Etoposide required in the Pivotal Study are shown below.

See Study Design

% of Patients with dose
reductions of carboplatin

Graph illustrating the percentage of ES-SCLC patients with dose reductions of carboplatin in the Pivotal StudyPROPORTION OF PATIENTS (%)25%2%0%10%20%30%40%E/P/A REGIMENE/P/A REGIMEN WITH COSELA(N=53)(N=54)

% of Patients with dose
reductions of Etoposide

Graph illustrating the percentage of ES-SCLC patients with dose reductions of etoposide in the Pivotal StudyPROPORTION OF PATIENTS (%)26%0%10%20%30%40%E/P/A REGIMENE/P/A REGIMEN WITH COSELA6%(N=53)(N=54)

E/P/A Regimen Arm = E/P/A + Placebo. Supportive care was allowed in either arm as described in the Pivotal Study.

Event rate per cycle was 0.021 vs 0.085.

No dose reduction was allowed for atezolizumab or COSELA (1st-Line).

INCIDENCE OF CHEMOTHERAPY DOSE REDUCTIONS IN STUDIES 2 AND 3

STUDIES 2 AND 3 ENDPOINTS: The number of all-cause dose reductions, events per 100 cycles, was 2.2 with COSELA vs 8.4 without COSELA in Study 2, and 5.1 with COSELA vs 11.6 without COSELA in Study 3. Dose reductions of Etoposide/Carboplatin and Topotecan are shown.

See Study Design

STUDY 2: % of Patients with dose reductions of CARBOPLATIN/ETOPOSIDE1

Graph illustrating the percentage of ES-SCLC patients with dose reductions of carboplatin/etoposide in Study 235%8%0%10%20%30%40%E/P REGIMENE/P REGIMEN WITH COSELA(N=38)(N=39)PROPORTION OF PATIENTS (%)

E/P Regimen Arm = E/P + Placebo. Supportive care was allowed in either both arms as described In the Pivotal Study.

STUDY 3: % of Patients with Dose Reductions
of Topotecan2

Graph illustrating the percentage of ES-SCLC patients with dose reductions of topotecan in Study 331%19%0%10%20%30%40%TOPOTECANREGIMENTOPOTECANREGIMEN WITHCOSELA(N=29)(N=32)PROPORTION OF PATIENTS (%)

Topotecan Regimen Arm = Topotecan + Placebo. Supportive care was allowed in both arms as described in the Pivotal Study.

Event rate per cycle was 0.022 vs 0.084 in Study 2 and 0.051 vs 0.116 in Study 3.

No dose reduction was allowed for COSELA (1st-Line).

INDICATION: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).